Unknown PHASE3 INTERVENTIONAL NCT00066898

ARISE - Aggressive Reduction of Inflammation Stops Events

Reduction of Vascular Inflammation and Coronary Atherosclerosis With AGI-1067, a V-Protectant, Reduces Cardiovascular Events in Patients With Coronary Artery Disease

Sponsor: AtheroGenics

Conditions Atherosclerosis Coronary Artery Disease Myocardial Infarction Unstable Angina

Interventions AGI-1067

Updated 7 times since 2017 Last updated: Sep 29, 2006 Started: Jun 30, 2003 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Atherosclerosis and Coronary Artery Disease, this trial is ongoing. The trial is conducted by AtheroGenics and has accumulated 7 data snapshots since 2003. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Sep 2020 — Jan 2021 [monthly]

Unknown Status PHASE3

▶ Show 2 earlier versions

Jun 2018 — Sep 2020 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AtheroGenics

Data source: AtheroGenics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom , Abington, United States , Akron, United States , Allentown, United States , Amarillo, United States , Appleton, United States , Arcadia, South Africa , Atlanta, United States , Auburn, United States , Austin, United States and 171 more locations